{
  "abstract": "Background/Objectives: First-line poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance is standard in advanced ovarian cancer, but direct comparisons between active regimens within biomarker-defined groups are limited. We compared survival outcomes after first-line PARPi maintenance according to BRCA mutation and homologous recombination deficiency (HRD) status. Methods: This single-center retrospective cohort included 218 patients who initiated olaparib, olaparib plus bevacizumab, or niraparib after first-line platinum-based chemotherapy. Progression-free survival (PFS) and overall survival (OS) were measured from maintenance initiation. We compared olaparib with niraparib in BRCA-mutated disease and olaparib plus bevacizumab with niraparib in HRD-positive, BRCA-wild-type disease. Results: Overall, 82 patients received olaparib, 33 olaparib plus bevacizumab, and 103 niraparib. Median follow-up was 23.9 months. In BRCA-mutated disease, 2-year PFS was 68.2% with olaparib (n = 81) and 69.0% with niraparib (n = 44; niraparib vs. olaparib: hazard ratio [HR] 1.14, 95% confidence interval [CI] 0.60–2.17; log-rank p = 0.695). In HRD-positive, BRCA-wild-type disease, 2-year PFS was 81.0% with olaparib plus bevacizumab (n = 22) and 62.6% with niraparib (n = 51; niraparib vs. combination: HR 1.58, 95% CI 0.61–4.09; log-rank p = 0.338). A bevacizumab-containing induction regimen was more frequent in the combination group (13/22 vs. 2/51), and only seven deaths occurred in this comparison. Conclusions: Neither comparison showed a statistically significant PFS difference, and the study was not powered to evaluate OS or to establish superiority or equivalence. The small HRD-positive comparison and differences in prior treatment preclude a definitive conclusion about the relative efficacy of olaparib plus bevacizumab and niraparib.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea",
    "Department of Obstetrics and Gynecology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Young Joo Choi"
    },
    {
      "affs": [
        1
      ],
      "name": "Jung-Yun Lee",
      "orcid": "0000-0001-7948-1350"
    },
    {
      "affs": [
        0
      ],
      "name": "Eun Ji Nam",
      "orcid": "0000-0003-0189-3560"
    },
    {
      "affs": [
        0
      ],
      "name": "Sang Wun Kim",
      "orcid": "0000-0002-8342-8701"
    },
    {
      "affs": [
        0
      ],
      "name": "Sunghoon Kim",
      "orcid": "0000-0002-1645-7473"
    },
    {
      "affs": [
        0
      ],
      "name": "Yong Jae Lee",
      "orcid": "0000-0003-0297-3116"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4fc9vyv2fwmf0.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18213508",
  "fulltext_url": null,
  "id": "4fc9vyv2fwmf0",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://www.mdpi.com/2072-6694/18/21/3508",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-31",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/4fc9vyv2fwmf0.ris",
  "sources": [
    {
      "first_seen": "2026-11-03T12:21:32Z",
      "native_id": "10.3390/cancers18213508",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/21/3508"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Comparison of Survival Outcomes with First-Line PARP Inhibitor Maintenance According to BRCA Mutation and Homologous Recombination Deficiency Status in Advanced Ovarian Cancer: A Single-Center Retrospective Cohort Study",
  "title_text": "Comparison of Survival Outcomes with First-Line PARP Inhibitor Maintenance According to BRCA Mutation and Homologous Recombination Deficiency Status in Advanced Ovarian Cancer: A Single-Center Retrospective Cohort Study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-05T00:21:09Z",
  "url": "https://research.draconitic.com/paper/4fc9vyv2fwmf0",
  "venue": "Cancers",
  "versions": []
}